Background: Post Transplant Lymphoproliferative Disorder (PTLD) is a rare but severe complication following renal transplant. This study aims to explore the treatment modalities, histological types, and risk factors related to PTLD. Methods: Following the PRISMA guideline, we searched the literature on PubMed, Cochrane, Embase & clinicaltrials.gov. A total of 1741 articles were screened and 16 studies were included. Results: We reviewed 275915 adult patients who underwent renal transplantation out of which 2484 (0.9%) patients developed PTLD. Data for gender shows that 61.1% were males and 38.9% females. 576/2484 (23%) cases were EBV positive post-transplant. Seven studies showed the median duration from transplant to the development of PTLD was 80 months (5m-22yrs). Monomorphic PTLD was reported in 585 cases as the most common histological type. 5 studies suggested mortality due to PTLD was 41.38%. OS at 5 and 10 years was 55% and 41% respectively. Conclusions: Our study shows that PTLD is a rare complication after renal transplant which was more common in males. EBV did not show association with PTLD. Monomorphic is the most common histological type of PTLD after renal transplant. Our results show that it is associated with significantly high mortality.

ATG: Anti thymocyte globulin AZA: Azathioprine BSL: Basiliximab CsA: Cyclosporin A CT: chemotherapy CNI: calcineurin inhibitor, D: donor HDVP 16 High dose Etoposide Tx: transplant mTOR: mammalian target of rapamycin mono: monomorphic m: months MMF: Mycophenolate mofetil M: mean poly: polymorphic R: recipient RIS: reduction in immunosuppression Rit: Rituximab RT: radiotherapy Tac: Tacrolimus y: year.